Intelligence · Clinical Pipeline
Eli Lilly and Pipeline
All ClinicalTrials.gov programs at Eli Lilly and — phase, modality, and trial IDs.
- Programs
- 25
Quick answer
Eli Lilly and has 25 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
A Phase 1 Study on the effects of LY3410738 (study drug) administered to Patients with Advanced Solid Tumors with IDH1 or IDH2 Mutations
Eli Lilly Co.
Patients with IDH1 R132, IDH2 R140 or IDH2 R172-mutant advanced solid tumor types, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma.
1 trial -
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors
Eli Lilly Co.
Advanced/metastatic solid tumor
1 trial -
A Single-Dose Pharmacokinetic Study of Eloralintide in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function
Eli Lilly Co.
Participants with Mild, Moderate, or Severe Hepatic Impairment and Participants with Normal Hepatic Function
1 trial -
A Single-Dose Pharmacokinetic Study of Lepodisiran in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function
Eli Lilly Co.
Normal Hepatic Function and Mild, Moderate, or Severe Hepatic Impairment
1 trial -
A Study of LY3200882 in Participants With Solid Tumors.
Eli Lilly Co.
Metastatic cancer, Solid Tumor
1 trial -
A Study of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment
Eli Lilly Co.
Healthy, Hepatic Insufficiency
1 trial -
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly Co.
Metastatic Solid Tumor Advanced Solid Tumor Non-small Cell Lung Cancer SMARCA4-Deficient Tumor
1 trial -
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly Co.
Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
1 trial -
A Study of LY4057996 in Healthy Participants and Participants with Type 1 and Type 2 Diabetes (YKAA)
Eli Lilly Co.
Healthy, Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2
1 trial -
A Study of LY4175408 in Participants With Advanced or Metastatic Solid Tumors.
Eli Lilly Co.
Cancer
1 trial -
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Eli Lilly Co.
Breast Neoplasms Colorectal Neoplasms Prostate Neoplasm Endometrial Neoplasms Neoplasm Metastasis
1 trial -
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants with Type 1 Diabetes Mellitus.
Eli Lilly Co.
Type 1 Diabetes Mellitus
1 trial -
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Eli Lilly Co.
Diabetes Mellitus
1 trial -
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
Eli Lilly Co.
Type 2 Diabetes Mellitus
1 trial -
A study of LOXO-783 in Patients with PIK3CA H1047R-Mutant Advanced Breast Cancer and Other Solid Tumors.
Eli Lilly Co.
Advanced Breast Cancer and Other Solid Tumors
1 trial -
A study of the PAN-KRAS inhibitor LY4066434 in participants with KRAS mutant solid tumors.
Eli Lilly Co.
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor Metastatic Solid Tumor, PanKRAS.
1 trial -
A study to assess the pharmacokinetics, and glucodynamics of LY3209590 in participants with type 2 diabetes
Eli Lilly Co.
Type 2 Diabetes Mellitus
1 trial -
A study to characterise the safety, tolerability and efficacy of LY3962673 in subjects with advanced solid tumors.
Eli Lilly Co.
KRAS G12D-mutant solid tumors.
1 trial -
A study to characterise the safety, tolerability and efficacy of LY4170156 in subjects with advanced solid tumors
Eli Lilly Co.
Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lung cancer, triple-negative breast cancer, pancreatic cancer and colorectal cancer.
1 trial -
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Eli Lilly Co.
Prostatic Neoplasms
1 trial -
EMBER: A Study of LY3484356 in Patients with Breast or Other Non-Breast Cancers
Eli Lilly Co.
Breast Cancer, Endometrial cancer
1 trial -
J1O-MC-JZHD: A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
Eli Lilly Co.
Neuroblastoma
1 trial -
Multiple Ascending Dose Study of LY4256984 in Participants with Sporadic Amyotrophic Lateral Sclerosis
Eli Lilly Co.
Sporadic Amyotrophic Lateral Sclerosis
1 trial -
Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations.
Eli Lilly Co.
Advanced Hematologic Malignancies
1 trial -
Study of Abemaciclib with Pembrolizumab in Patients with Stage IV Lung Cancer or Breast Cancer
Eli Lilly Co.
Lung Cancer or Breast Cancer
1 trial
Frequently asked questions
How many pipeline programs does Eli Lilly and have?
25 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs